Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Pegasys

Roche - Basel

Strong sales in breast cancer lift Roche revenues

New products Perjeta and Kadcyla lead growth

- PMLiVE

Olysio drives J&J pharma sales

But hepatitis C drug set to face serious competition from Gilead Sciences

Gilead Sciences

Gilead gets US approval for Sovaldi follow-up Harvoni

Company claims it could cure 90 percent of patients within eight weeks

Bristol Myers Squibb logo

BMS drops US application for ‘breakthrough’ hep C combination

Blames the 'rapidly evolving' market for asunaprevir withdrawal

- PMLiVE

Roche appoints Philip Atkinson to new global role

He will lead the company's new scientific communications group

- PMLiVE

Breast cancer drug market set to double in 10 years

New entrants will join market leaders Roche, Novartis and AstraZeneca

- PMLiVE

PD1 drugs could end ‘decades of silence’ in bladder cancer therapy

Merck's Keytruda and Roche antibody showing promise

- PMLiVE

Janssen, AZ and Roche at ESMO

Companies present promising data on new cancer drugs

Gilead Sciences

Gilead’s hep C combination Harvoni recommended for EU approval

CHMP backs combination of Sovaldi and ledipasvir

Roche's Perjeta pertuzumab

Roche’s Perjeta should be ‘new standard’ in breast cancer

Could improve survival when added to therapy with Herceptin and docetaxel

- PMLiVE

Awards recognise hepatitis C care in UK

First QiC Hepatitis C takes place at BASL conference

- PMLiVE

Roche’s Julie Warner joins Boyds

She takes up appointment as an associate director at the drug development consultancy

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links